Get the Stockscreener App
2.9032
4.06%
0.1132
Galectin Therapeutics Inc stock is traded at $2.9032, with a volume of 67,306.
It is up +4.06% in the last 24 hours and down -2.58% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.79
Open:
$2.78
24h Volume:
67,306
Relative Volume:
0.20
Market Cap:
$186.33M
Revenue:
-
Net Income/Loss:
$-37.30M
P/E Ratio:
-4.9099
EPS:
-0.5913
Net Cash Flow:
$-30.62M
1W Performance:
-0.91%
1M Performance:
-2.58%
6M Performance:
-30.55%
1Y Performance:
+130.41%
1-Day Range:
$2.78
$2.92
1-Week Range:
$2.55
$3.00
52-Week Range:
$1.12
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.89 | 179.88M | 0 | -37.30M | -30.62M | -0.5913 |
VRTX
Vertex Pharmaceuticals Inc
|
452.84 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.39 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
745.58 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.62 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.73 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee - Stock Titan
Galectin Therapeutics Reports 2025 Financial Results, Advances Belapectin Program for MASH Cirrhosis, and Extends Cash Runway Through 2027 - Minichart
Galectin Therapeutics Reports 2025 Financial Results - National Today
Galectin Therapeutics 2025 Annual Report: Clinical Trials, Regulatory Challenges, and Biopharma Industry Risks - Minichart
Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs - TradingView
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update - Yahoo Finance
NAVIGATE MASH data and funding risks at Galectin (NASDAQ: GALT) - Stock Titan
Belapectin data and $30.8M 2025 loss at Galectin (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics 10-K: R&D cuts reduce cash burn; cash runway to Apr 2027 - TradingView
What makes Galectin Therapeutics Inc stock attractive today2026 Trade Ideas & Low Risk High Win Rate Picks - baoquankhu1.vn
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 27.0% in March - MarketBeat
Risk Recap: Is Galectin Therapeutics Inc in a bullish channel2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
Retail Trends: Is Galectin Therapeutics Inc gaining market share2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
Galectin Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Aug Gainers: Does Galectin Therapeutics Inc stock have upside surprise potential2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Galectin Therapeutics (FRA:PHPN) PB Ratio : (As of Mar. 25, 2026) - gurufocus.com
Galectin Therapeutics (GALT) Projected to Post Earnings on Monday - MarketBeat
Wall Street Recap: What makes Galectin Therapeutics Inc stock attractive today - baoquankhu1.vn
Galectin Therapeutics Stock (ISIN: US3631621074) Faces Investor Scrutiny Amid Legal Probe and Earnin - AD HOC NEWS
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board - The Globe and Mail
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps - Defense World
Galectin Therapeutics Appoints Dr. Henry Brem to Board, Advancing Belapectin for MASH Cirrhosis and Cancer Therapies - Minichart
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board By Investing.com - Investing.com India
Galectin Therapeutics Inc. Appoints Henry Brem, M.D. as Independent Director to Board of Directors - marketscreener.com
Sentiment Recap: Is Galectin Therapeutics Inc forming a double bottom2026 Trade Ideas & Consistent Growth Equity Picks - baoquankhu1.vn
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board - Investing.com
Galectin Therapeutics (GALT) director awarded 60,000 stock options at $3.1600 - Stock Titan
Director Henry Brem joins Galectin (GALT) board and reports zero share ownership - Stock Titan
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. - Bitget
Henry Brem, M.D. joins Galectin Therapeutics (GALT) Board as independent director - Stock Titan
Portfolio Shifts: Whats the outlook for Galectin Therapeutics Incs sectorTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Recap Report: Is Galectin Therapeutics Inc forming a double bottomQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Take Profit: Does Galectin Therapeutics Inc have a sustainable dividendJuly 2025 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Panic Selling: Will Galectin Therapeutics Inc outperform its industry peers2025 Price Momentum & Weekly Stock Breakout Alerts - baoquankhu1.vn
Highs Report: Is Galectin Therapeutics Inc forming a double bottomJuly 2025 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Buyout Rumor: Can Galectin Therapeutics Inc weather a recessionJuly 2025 Summary & Reliable Intraday Trade Alerts - baoquankhu1.vn
GALT Should I Buy - Intellectia AI
GALT SEC FilingsGalectin Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET - marketscreener.com
GALT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GALT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT - TipRanks
Is Galectin Therapeutics Inc. in a bullish channel2025 Short Interest & Weekly Breakout Watchlists - mfd.ru
Trend Review: Is Galectin Therapeutics Inc in a bullish channelJuly 2025 Decliners & AI Forecast Swing Trade Picks - baoquankhu1.vn
Does Galectin Therapeutics Inc. have a sustainable dividendWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
Is Galectin Therapeutics Inc stock a buy or sell2025 Earnings Surprises & Low Risk High Win Rate Picks - baoquankhu1.vn
What is the long term forecast for Galectin Therapeutics Inc. stock2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
GALT PE Ratio & Valuation, Is GALT Overvalued - Intellectia AI
Will Galectin Therapeutics Inc. stock deliver long term returns2025 Volatility Report & Safe Capital Allocation Plans - mfd.ru
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
1.44%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):